Ian M. Adcock

Dovehouse Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 348 publications

Improved peripheral airway reactance is associated with clinical remission following biologic therapy in severe asthma.

Improved peripheral airway reactance is associated with clinical remission following biologic therapy in severe asthma.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: June 11, 2026

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

Journal: Allergy
Published: March 31, 2026

Genome-wide association study of asthma with high treatment burden and/or worse outcomes defined using electronic healthcare data in UK Biobank.

Genome-wide association study of asthma with high treatment burden and/or worse outcomes defined using electronic healthcare data in UK Biobank.

Journal: ERJ open research
Published: February 27, 2026

Managing multimorbidity in severe asthma: comparison of resources and perspectives between severe asthma specialists and general respiratory physicians across Europe.

Managing multimorbidity in severe asthma: comparison of resources and perspectives between severe asthma specialists and general respiratory physicians across Europe.

Journal: ERJ open research
Published: February 17, 2026

The crucial role of normative ageing in respiratory pathogenesis.

The crucial role of normative ageing in respiratory pathogenesis.

Journal: The lancet. Healthy longevity
Published: February 10, 2026

Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.

Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.

Journal: Allergy
Published: January 24, 2026

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Journal: Allergy
Published: January 21, 2026

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Journal: Allergy
Published: January 21, 2026

Small Airway Dysfunction May Mediate the Association Between Body Mass Index and Severe Asthma Exacerbations.

Small Airway Dysfunction May Mediate the Association Between Body Mass Index and Severe Asthma Exacerbations.

Journal: The European respiratory journal
Published: January 20, 2026

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Journal: Lung
Published: January 13, 2026

Clinical Features of Cellular Senescence Pathways in Severe Asthma.

Clinical Features of Cellular Senescence Pathways in Severe Asthma.

Journal: Allergy
Published: December 13, 2025

MiR-146a-armed exosomes reverse immunosuppressive networks in NSCLC by dual-targeting of MYD88/STAT3 and PD-L1 axes.

MiR-146a-armed exosomes reverse immunosuppressive networks in NSCLC by dual-targeting of MYD88/STAT3 and PD-L1 axes.

Journal: International immunopharmacology
Published: December 08, 2025
Showing 1-12 of 348

Last Updated: 09/26/2026